We were able to rank most of the psychotropics based on the available evidence and recommendations from subject matter experts .
There were few discrepancies between published evidence and the expert panel in ranking these drugs .
Conclusion Potential for weight gain is an important consideration in choice of any psychotropic .
This tool will help clinicians select psychotropics on a case-by-case basis in order to minimize the impact of weight gain when making both intra-class and interclass choices
Introduction Psychotropic medication use is associated with  weight gain .
While there are studies and review s comparing weight gain for psychotropics within some classes , clinicians frequently use drugs from different classes to treat psychiatric disorders .
Objective To undertake a systematic review of all classes of psychotropics to provide an all encompassing evidence -based tool that would allow clinicians to determine the risks of weight gain in making both intra-class and interclass choices of psychotropics .
Atypical antipsychotic monitoring in the Kilkenny Mental Health Services.
OBJECTIVES To examine baseline testing and ongoing monitoring of cardiovascular and other risk factors in individuals prescribed atypical antipsychotic medications . METHODS We derived a list of baseline and ongoing monitoring tests from the literature ( Weight , BMI , blood pressure , U&E , LFTs , glucose , HbA1C , FBC , TFTs , prolactin , lipids & ECG ) and then review ed a r and om sample of 80 records of patients prescribed atypical antipsychotics and currently attending an Irish public catchment area service , for evidence of testing . RESULTS Levels of testing for baseline tests ranged from 45 % for blood pressure to 0 % for BMI . Levels of ongoing monitoring tests ranged from 42.5 % for U&E to 0 % for BMI . Patients admitted to hospital were much more likely to have had testing . CONCLUSIONS The need for baseline and ongoing monitoring of certain tests in patients prescribed atypical antipsychotics is increasingly accepted . Levels of such testing are currently quite low and need to increase
We were able to rank most of the psychotropics based on the available evidence and recommendations from subject matter experts .
There were few discrepancies between published evidence and the expert panel in ranking these drugs .
Conclusion Potential for weight gain is an important consideration in choice of any psychotropic .
This tool will help clinicians select psychotropics on a case-by-case basis in order to minimize the impact of weight gain when making both intra-class and interclass choices
Introduction Psychotropic medication use is associated with  weight gain .
While there are studies and review s comparing weight gain for psychotropics within some classes , clinicians frequently use drugs from different classes to treat psychiatric disorders .
Objective To undertake a systematic review of all classes of psychotropics to provide an all encompassing evidence -based tool that would allow clinicians to determine the risks of weight gain in making both intra-class and interclass choices of psychotropics .